

CE IVD




Leukemia Fusion Genes Screening & Quantification

Extensive real-time PCR assays for the detection of leukemia fusion genes to facilitate accurate diagnosis and therapeutic management

Common Symptoms of Leukemia

Leukemia, also known as blood cancer, usually begins in the bone marrow and results in high numbers of abnormal blood cells.

The exact cause of leukemia is unclear. A combination of genetic factors and environmental factors are believed to play a role.



Leukemia patients are often accompanied by chromosomal abnormalities. Abnormal genes formed by chromosomal recombination are called **fusion genes**, which code for fusion proteins with altered functionality.

A better understanding of leukemia fusion genes may benefit patient with leukemia by providing accurate diagnosis and classification, as well as the assessment of prognosis and treatment planning.

Real-time PCR based genetic testing is one of the most effective methods.¹

Screening

Targeted Therapy

BCR-ABL1: The BCR-ABL1-positive patient may benefit from tyrosine kinase inhibitor (TKI) therapy.²

 $\begin{array}{l} \textbf{PML-RAR}\alpha: \mbox{All-trans retinoic acid (ATRA) and arsenic} \\ \mbox{trioxide are treatment options for the patient with} \\ \mbox{PML-RAR}\alpha\mbox{ positive.}^{3.4} \end{array}$

Prognosis

CBF β -MYH11, PML-RAR α , AML1-ETO may indicate a relatively favorable prognosis.⁵

Quantification

Treatment Monitoring

See how patients respond to treatment by measuring the level of specific genes periodically.

Minimal Residual Disease (MRD) Testing

Measuring MRD is an important way to understand whether the patient is getting the most effective treatment to ensure a lasting remission from leukemia.⁶

1. Understanding Lab and Imaging Tests. Leukemia & Lymphoma Society. 2020

2. Tyrosine kinase inhibitor (TKI) therapy. Leukemia & Lymphoma Society. Available from: https://www.lls.org/

3. Raffoux E, et al. Journal of clinical oncology, 2003, 21(12): 2326-2334.

4. Estey E, et al. Blood, 2006, 107(9): 3469-3473.

- 5. Schnittger S, et al. Blood, 2003, 102(8): 2746-2755.
- 6. Minimal Residual Disease (MRD) | Leukemia & Lymphoma Society. 2019

Key Features



Sample Type: Blood or bone marrow



Compatible with common real-time PCR thermal cyclers



Screening of up to 52 fusion genes in one kit



Short TAT: within 3 hours

***** Leukemia Fusion Genes Screening Kits

No.	Product				Product			NL	Product		
	Q30	Q51	Fusion Gene	No.	Q30	Q51	Fusion Gene	No.	Q30	Q51	Fusion Gene
1	•	*	MLL-AF9	19	٠	*	MLL-AF17	37		*	CALM-AF10
2	٠	*	AML1-ETO	20	٠	*	NPM-RARα	38		*	HOX11
3	٠	*	MLL-AF4	21	٠	*	NPM-MLF1	39		*	TEL-JAK2
4	•	*	TEL-AML1	22	٠	*	PLZF-RARα	40		*	MLL-AFX1
5	•	*	E2A-PBX1	23	٠	*	MLL-AF1q	41		*	ETV6-PDFGRA
6	•	*	MLL-ENL	24	٠	*	MLL-AF1P	42		*	HOX11L2
7	•	*	SIL-TAL1	25	٠	*	TEL-ABL1	43		*	dup MLL
8	٠	*	MLL-AF10	26	٠	*	AML1-MTG16	44		*	NUP98-PMX1
9	٠	*	CBFβ-MYH11	27	٠	*	AML1-EAP	45		*	NUP98-HOXD13
10	٠	*	AML1-MDS1/EV11	28	٠	*	MLL-AF6	46		*	NUP98-HOXA9
11	٠	*	FIP1L1-PDGFRA	29		*	EVI1	47		*	NUP98-HOXA13
12	٠	*	SET-CAN	30	٠		BCR-ABL1	48		*	NUP98-HOXC11
13	٠	*	E2A-HLF	31		*	BCR-ABL1 p190	49		*	NUP98-HOXA11
14	٠	*	DEK-CAN	32		*	BCR-ABL1 p210	50		*	STAT5-RARα
15	٠	*	MLL-SEPT6	33	٠		PML-RARα	51		*	NUMA-RARα
16	٠	*	TLS-ERG	34		*	PML-RARα S	52		*	FIPIL1-RARα
17	٠	*	TEL-PDGFRB	35		*	PML-RARα V	53		*	PRKAR1A-RARα
18	•	*	MLL-ELL	36		*	PML-RARα L	54		*	NPM-ALK

Targets included in Q30 kit

★ Targets included in Q51 kit

Applicable for the real-time PCR thermal cycler with FAM, HEX, ROX and Cy5 detection channels.

Validated real-time PCR models: CFX96, ABI7500, Light Cycler 96, Mx3005P / 3000P, SLAN 96s

👏 Quantification of Specific Leukemia Fusion Genes

BCR-ABL1 Genetic Testing

The presence of the gene sequence known as BCR-ABL1 confirms the diagnosis of CML and a form of acute lymphoblastic lymphoma (ALL), called Philadelphia chromosome (Ph)-positive ALL.

Once CML or Ph-positive ALL has been diagnosed, BCR-ABL1 quantitative genetic testing is ordered periodically (typically every 3 months) to monitor the response to treatment and monitor for recurrence.

- BCR-ABL1 Genotyping Kit: Differentiation of BCR-ABL1 p210, BCR-ABL1 p190, BCR-ABL1 p230 splice variants
- BCR-ABL1 p190 Kit: Quantification of BCR-ABL1 p190 transcripts
- BCR-ABL1 p210 Kit: Quantification of BCR-ABL1 p210 transcripts

PML-RARα Genetic Testing

Up to 98% of cases of acute promyelocytic leukemia (APL), a subtype of AML, have a characteristic t(15;17) PML-RARα reciprocal chromosomal translocation.

Definitive diagnosis of APL requires testing for the PML-RAR α fusion gene.

- PML-RARα Genotyping Kit: Differentiation of the subtype of PML-RARα L, S and V transcripts
- PML-RARα L Detection Kit: Quantification of PML-RARα L transcripts
- PML-RARα S Detection Kit: Quantification of PML-RARα S transcripts
- PML-RARa V Detection Kit: Quantification of PML-RARa V transcripts

Quantification Kits for Other Fusion Genes

The detection kits of 55 fusion genes are available individually. Please contact your sales representative or local distributor for more details.

👏 Ordering Information

Cat. No	Product	Size
803041	Leukemia Fusion Genes (Q30) Screening Kit	20 Tests/Kit
803100	Leukemia Fusion Genes (Q51) Screening Kit	20 Tests/Kit
803317	BCR-ABL1 p190 Kit	20 Tests/Kit
803318	BCR-ABL1 p210 Kit	20 Tests/Kit
803215	BCR-ABL1 Genotyping Kit	20 Tests/Kit
803212	PML-RARa L Detection Kit	20 Tests/Kit
803213	PML-RARa S Detection Kit	20 Tests/Kit
803214	PML-RARa V Detection Kit	20 Tests/Kit
803216	PML-RARa Genotyping Kit	20 Tests/Kit
803209	AML1-ETO Detection Kit	20 Tests/Kit
803319	WT1 Detection Kit	20 Tests/Kit
803409	CBFβ-MYH11 Detection Kit	20 Tests/Kit
	Quantitative Detection Kits for Other Fusion Genes	20 Tests/Kit

Xiamen Zeesan Biotech Co., Ltd.

No. 884-1 and 884-2 Lianting Road, (Xiang An) Industrial Area, Torch High-Tech Zone, Xiamen City, Fujian Province, 361101, P.R. China

Phone: +86-592-7615091 **E-mail:** info@zsandx.com